MEDICUS PHARMA LTD
MDCXNASDAQTrading Snapshot
- Day Range
- $0.16 – $0.16
- 52-Week Range
- $0.14 – $2.78
- Volume
- $2.65B
- Avg Volume
- $2.34B
- Shares Outstanding
- 22.0M
- Next Earnings
- Dec 7, 2026
Fundamentals Snapshot
- Annual Revenue
- $1M
- Last Q Revenue
- $292,749
- P/E Ratio
- -0.1
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.71
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +113.1%
Why Investors Own MDCX
- ✓High-growth profile — revenue up +29.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 29% gross margin and 7% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
MEDICUS PHARMA LTD
MDCX
StockOtter · stockotter.spaceAbout MEDICUS PHARMA LTD
Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Medicus Pharma files streamlined Phase 2b/3 prostate cancer trial design with FDA
Medicus Pharma (NASDAQ:MDCX) has submitted a seamless Phase 2b/3 registration-intent protocol to the US Food and Drug Administration for Teverelix, its long-acting GnRH antagonist for advanced prostate cancer patients at
Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer
Proposed seamless design would incorporate previously FDA-cleared dose-optimization work into a single registration-intent program aligning it with Company's capital-efficient development strategy Proposed seamless desig
Medicus Pharma to focus SkinJect development exclusively on Gorlin syndrome patients
Medicus Pharma (NASDAQ:MDCX) said it will focus future internally sponsored clinical development of SkinJect exclusively on Gorlin syndrome patients with multiple basal cell carcinoma lesions and will conclude further de
Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment
PHILADELPHIA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd.
Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI
Medicus Pharma (NASDAQ:MDCX) earlier this week outlined progress across its SkinJect program and a co-development and licensing opportunity with Pfizer, with CEO Raza Bokhari highlighting clinical, partnership and fundin
Wall Street sets positive tone as investors digest hotter inflation data
Positive tone Wall Street opened sharply higher on Friday, with the Dow Jones Industrial Average and S&P 500 both gaining 1.1% and the Nasdaq rising 1.2% as...